Evidence map›Paper›PMID 34189675›Full record

ArticleClinical rheumatology2021

Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up.

Rocío-V Gamboa-Cárdenas, Silvia Barzola-Cerrón, Denisse Toledo-Neira, Cristina Reátegui-Sokolova, Víctor Pimentel-Quiroz, Francisco Zevallos-Miranda, Graciela S Alarcón, Manuel Ugarte-Gil

Open access · bronzeAbstract read
In one paragraph

Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Rocío-V Gamboa-CárdenasGrupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru. rvgc1@yahoo.com.ORCID http://orcid.org/0000-0002-2870-0522
Silvia Barzola-CerrónRheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen EsSalud, Lima, Peru.
Denisse Toledo-NeiraRheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen EsSalud, Lima, Peru.
Cristina Reátegui-SokolovaRheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen EsSalud, Lima, Peru.
Víctor Pimentel-QuirozGrupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru.
Francisco Zevallos-MirandaRheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen EsSalud, Lima, Peru.
Graciela S AlarcónDivision of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama At Birmingham, Birmingham, AL, USA.
Manuel Ugarte-GilGrupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru.
Hospital Base Guillermo Almenara Irigoyen · PEUniversidad Científica del Sur · PEUniversidad Peruana Cayetano Heredia · PEUniversidad San Ignacio de Loyola · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe identification of risk factors for COVID-19 adverse course in autoimmune rheumatic diseases (ARDs) is of the utmost importance when approaching patient management; however, data are scarce in relation to the Latin American population. The objective of this study was to determine predictors of hospitalization for COVID-19 patients from an ARD community cohort.

methodsA real setting longitudinal study (March to November 2020) in an ARD community cohort was carried out. Potential predictors of hospitalization for COVID-19 examined included (1) sociodemographic variables (age, gender, education, tobacco use, socioeconomic status, and co-inhabitants), (2) comorbidities, (3) time to COVID-19 diagnosis, and (4) ARD's features: clinical (disease type, disease duration, activity), treatment [corticosteroids use/doses, use of synthetic DMARDs (cDMARDs, tsDMARDs, and bDMARDs)], treatment schedule and non-adherence, and the Multidimensional Health Assessment Questionnaire (MDHAQ). Univariable and multivariable regression analysis were conducted; OR and 95% CI (p < 0.05) were determined.

resultsOne thousand and one hundred forty-eight patients with ARDs were included; 154 had COVID-19; of these 139 (90.3%) were women, aged 52.5 (13.7) years; 33.1% had hypertension and 61.0% an affected organ by ARD. Infection was detected 8.4 (10.1) days after symptoms started; there were 33 hospitalized patients (rate 21.4%). Predictors of hospitalization by multivariable analysis were age (OR: 1.06; CI: 1.01-1.10; p: 0.01), comorbidities: hypertension (OR: 3.95; 95% CI: 1.40-10.95, p: 0.01) and neoplasm (OR: 9.0; 95% CI: 1.6-52.3; p: 0.01), number of organs involved by ARD (OR: 2.26; 95% CI: 1.16-4.41; p: 0.02), and infection diagnosis delay (OR: 1.36; 95% CI: 1.03-1.80; p: 0.01).

conclusionsIn our ARD patients with COVID-19, older age, comorbidities (neoplasm and hypertension), and a delay in COVID-19 diagnosis were predictors of hospitalization. The only ARD-associated predictor feature was the number of organs involved. Key Points • Patients with ARD and COVID-19 have an adverse course in comparison to the general population. • Previous predictors of COVID-19 hospitalization, including known risk factors (such as older age and comorbidities) and systemic manifestations, should be taken into account in the management of these patients. • Delayed diagnosis of COVID-19 impacts negatively on prognosis. • Availability of diagnostic tests is of utmost importance.

Indexed as

Autoimmune DiseasesCOVID-19Rheumatic DiseasesAgedCOVID-19 TestingFemaleFollow-Up StudiesHospitalizationHumansLongitudinal StudiesRisk FactorsSARS-CoV-2Autoimmune rheumatic diseaseCOVID-19COVID-19 adverse predictorsSARS-CoV-2

Identifiers

PMID34189675
PMCPMC8241466
OpenAlexW3177261274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.